CJC-1295 dosage in research

The Teichman experiment

The 2006 study by Teichman and colleagues tested CJC-1295 DAC in healthy adults aged 21-61. Single subcutaneous doses of 30 or 60 micrograms/kg produced prolonged changes in growth hormone and IGF-1. The study also examined multiple doses.

The unit is micrograms per kilogram of body weight. It describes how the researchers allocated material in that experiment. The published work established early pharmacokinetics and hormone responses; it supplied no approved personal-treatment dose.

I distrust dose summaries that preserve a number and discard the population. Here the healthy-volunteer setting, the DAC form and the measured hormone response are inseparable from the amount.

The Ionescu/Frohman experiment

Ionescu and Frohman’s 2006 experiment involved healthy men aged 20-40. They received a single subcutaneous dose of 60 or 90 micrograms/kg. A week later, basal growth hormone was approximately 7.5-fold higher, with pulse frequency and magnitude unaltered.

The question was how secretion behaved under sustained GHRH-analog stimulation. I read the reported amounts as experimental conditions: they explain how the question was investigated. They cannot establish a safe regimen for a different person or for the short-acting no-DAC form.

The knockout-mouse experiment

In Alba and colleagues’ study, mice lacking GHRH received 2 micrograms at 24-hour, 48-hour or 72-hour intervals. The 24-hour interval normalised weight and length, while longer intervals were progressively less effective.

This is animal-only evidence from a particular growth-deficiency model. The result documents restoration of growth in those mice. It supplies no validated human amount or interval.

No established personal dose

CJC-1295 has no approved human indication, and the human hormone studies were brief early experiments. Online personal-use protocols lack controlled human validation. The CJC-1295/ipamorelin combination also lacks an established safe personal amount.

Preparation and route questions often get folded into dosage searches. The published CJC-1295 experiments principally used subcutaneous administration. Laboratory handling details do not settle clinical safety, so this page provides no preparation steps, injection sites or personal schedule.

The part of the file that still needs filling is clinical: worthwhile outcomes and reliable harm estimates over time. The effects discussion identifies those gaps; the half-life page explains why a long hormone response gives them added weight.